Play Video
1
Translating Ticagrelor
Translating Ticagrelor's Pharmacokinetics
::2013/05/17::
Play Video
2
Ticagrelor Trumps Clopidogrel for Vascular and Bleeding Outcomes
Ticagrelor Trumps Clopidogrel for Vascular and Bleeding Outcomes
::2012/09/27::
Play Video
3
Prasugrel and Ticagrelor in STEMI Patients
Prasugrel and Ticagrelor in STEMI Patients
::2013/04/10::
Play Video
4
Will AstraZeneca
Will AstraZeneca's ticagrelor make Effient and Plavix obsolete?
::2009/10/02::
Play Video
5
Benefit of Ticagrelor in Plato - Clinical Implications
Benefit of Ticagrelor in Plato - Clinical Implications
::2013/05/16::
Play Video
6
Flash Lecture: Ticagrelor vs. Clopidogrel in Patients with Stroke or TIA
Flash Lecture: Ticagrelor vs. Clopidogrel in Patients with Stroke or TIA
::2012/03/12::
Play Video
7
Uso del ticagrelor en el síndrome coronario agudo
Uso del ticagrelor en el síndrome coronario agudo
::2013/02/23::
Play Video
8
Ticagrelor Effects on MI Outcomes and Event Adjudication in PLATO
Ticagrelor Effects on MI Outcomes and Event Adjudication in PLATO
::2014/04/18::
Play Video
9
BRILINTA (ticagrelor) Launches "Complete the Course"  ...
BRILINTA (ticagrelor) Launches "Complete the Course" ...
::2012/09/19::
Play Video
10
Prasugrel y Ticagrelor en SCA
Prasugrel y Ticagrelor en SCA
::2012/06/20::
Play Video
11
The Effect of Ticagrelor in ACS -- Platelet and Non Platelet Dependent  Mechanisms | Doron Zahger
The Effect of Ticagrelor in ACS -- Platelet and Non Platelet Dependent Mechanisms | Doron Zahger
::2014/06/09::
Play Video
12
hm_Apixaban, Ticagrelor Both Winners
hm_Apixaban, Ticagrelor Both Winners
::2013/01/08::
Play Video
13
WEBM Dra  Camila Ramos nuevos antiagregantes ticagrelor y praugrel
WEBM Dra Camila Ramos nuevos antiagregantes ticagrelor y praugrel
::2014/04/21::
Play Video
14
Why do I Use Ticagrelor in STEMI Patients | Elad Asher
Why do I Use Ticagrelor in STEMI Patients | Elad Asher
::2014/06/09::
Play Video
15
Ticagrelor: de la teoría a la práctica. Experiencia de uso en el día a día. Dr. Radke
Ticagrelor: de la teoría a la práctica. Experiencia de uso en el día a día. Dr. Radke
::2012/10/19::
Play Video
16
The PLATO CABG analysis: Another feather in the cap for ticagrelor?
The PLATO CABG analysis: Another feather in the cap for ticagrelor?
::2010/08/19::
Play Video
17
Nuevo Antiagregantes: Prasugrel y Ticagrelor XIV Congreso SEMES CV
Nuevo Antiagregantes: Prasugrel y Ticagrelor XIV Congreso SEMES CV
::2011/11/29::
Play Video
18
Over-the-Top Brilinta (ticagrelor) Pharma Display
Over-the-Top Brilinta (ticagrelor) Pharma Display
::2014/03/29::
Play Video
19
The PLATO STEMI subanalysis: Will ticagrelor become the new go-to drug for antiplatelet therapy?
The PLATO STEMI subanalysis: Will ticagrelor become the new go-to drug for antiplatelet therapy?
::2010/04/30::
Play Video
20
7  Steg
7 Steg
::2014/04/03::
Play Video
21
Insidermedicine In 60 - January 13, 2010
Insidermedicine In 60 - January 13, 2010
::2010/01/14::
Play Video
22
GLOBAL LEADERS STUDY
GLOBAL LEADERS STUDY
::2013/05/16::
Play Video
23
Aterosclerosi e Trombosi - Meccanismi fisiopatologici e progressi clinici
Aterosclerosi e Trombosi - Meccanismi fisiopatologici e progressi clinici
::2013/01/16::
Play Video
24
CV drugs interaction
CV drugs interaction
::2014/02/11::
Play Video
25
The QAS Coronary Artery Reperfusion CPP
The QAS Coronary Artery Reperfusion CPP
::2014/04/29::
Play Video
26
Brilinta, Astrazeneca
Brilinta, Astrazeneca
::2012/08/23::
Play Video
27
Rachel Harris, question 3
Rachel Harris, question 3
::2013/02/25::
Play Video
28
Michael Callaghan, question 3
Michael Callaghan, question 3
::2013/02/27::
Play Video
29
Dr. Scott Wilson, question 3
Dr. Scott Wilson, question 3
::2013/02/25::
Play Video
30
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on ...
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on ...
::2013/08/05::
Play Video
31
Challenges for Post-PCI Antiplatelet Drugs
Challenges for Post-PCI Antiplatelet Drugs
::2012/04/23::
Play Video
32
FDA on the Brilinta approval
FDA on the Brilinta approval
::2011/07/26::
Play Video
33
High-Sensitivity Troponin as a Biomarker: A PLATO Substudy
High-Sensitivity Troponin as a Biomarker: A PLATO Substudy
::2012/12/17::
Play Video
34
Kim Kelly, question 3
Kim Kelly, question 3
::2013/02/25::
Play Video
35
Modulo SCACEST
Modulo SCACEST
::2014/04/08::
Play Video
36
Stephanie Young, question 3
Stephanie Young, question 3
::2013/02/25::
Play Video
37
Dia_internacional_del_donante_de_sangre.mpg
Dia_internacional_del_donante_de_sangre.mpg
::2011/06/27::
Play Video
38
Omg Atlanta
Omg Atlanta
::2014/02/14::
Play Video
39
Stroke - Preventing Stroke and TIA
Stroke - Preventing Stroke and TIA
::2013/05/31::
Play Video
40
Trends in the Management and Outcome of STEMI Patients
Trends in the Management and Outcome of STEMI Patients
::2013/05/16::
Play Video
41
4 - Understanding and management of TIAs in BC
4 - Understanding and management of TIAs in BC
::2010/01/25::
Play Video
42
adjudication for Study in C
adjudication for Study in C
::2013/04/18::
Play Video
43
Flash Lecture: Easy Finding Women with CVD Symptoms
Flash Lecture: Easy Finding Women with CVD Symptoms
::2012/04/26::
Play Video
44
Panel Discussion
Panel Discussion
::2014/06/09::
Play Video
45
Acute Coronary Syndromes at the European Society of Cardiology (ESC) Congress 2009
Acute Coronary Syndromes at the European Society of Cardiology (ESC) Congress 2009
::2009/09/16::
Play Video
46
Amie
Amie
::2011/12/17::
Play Video
47
Tia Physiotherapy 2
Tia Physiotherapy 2
::2010/01/25::
Play Video
48
Imitando a tia Teresinha
Imitando a tia Teresinha
::2011/02/21::
Play Video
49
The AHA 2009 EP update: PACE, REPLACE, and the potential of remote monitoring
The AHA 2009 EP update: PACE, REPLACE, and the potential of remote monitoring
::2010/04/15::
Play Video
50
Interventional Management of ACS in 2010
Interventional Management of ACS in 2010
::2013/05/16::
MAIS >>
RESULTADOS [51 .. 101]
Origem: Wikipédia, a enciclopédia livre.
Ir para: navegação, pesquisa
Ticagrelor
Alerta sobre risco à saúde
Ticagrelor.svg
Nome IUPAC (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-
3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-
hydroxyethoxy)cyclopentane-1,2-diol
Outros nomes AZD6140
Identificadores
Número CAS 274693-27-5
PubChem 9871419
Propriedades
Fórmula química C23H28F2N6O4S
Massa molar 522.55 g mol-1
Farmacologia
Via(s) de administração oral
Excepto onde denotado, os dados referem-se a
materiais sob condições PTN

Referências e avisos gerais sobre esta caixa.
Alerta sobre risco à saúde.

Ticagrelor (nome comercial Brilinta) é um fármaco inibidor da agregação plaquetária produzido pela AstraZeneca.[1]

Notas e referências

  1. RCM Pharma. Ticagrelor pertence a uma classe pioneira de medicamentos para tratamento antiplaquetário mais eficaz, proporcionando redução de eventos trombóticos em pacientes com síndrome coronariana aguda (SCA), também conhecidos como infarto ou angina instável (dor no peito). Painel da FDA com opiniões divergentes sobre o Brilinta® da AstraZeneca. Acesso em 29 de julho de 2010
Ícone de esboço Este artigo sobre fármacos é um esboço. Você pode ajudar a Wikipédia expandindo-o.
Conteúdo da Wikipedia está licenciado sob a: GFDL License
Powered by YouTube